Sedegah Martha, Belmonte Maria, Epstein Judith E, Siegrist Claire-Anne, Weiss Walter R, Jones Trevor R, Lu Minh, Carucci Daniel J, Hoffman Stephen L
Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910, USA.
J Immunol. 2003 Sep 15;171(6):3148-53. doi: 10.4049/jimmunol.171.6.3148.
In some parts of Africa, 50% of deaths attributed to malaria occur in infants less than 8 mo. Thus, immunization against malaria may have to begin in the neonatal period, when neonates have maternally acquired Abs against malaria parasite proteins. Many malaria vaccines in development rely upon CD8 cells as immune effectors. Some studies indicate that neonates do not mount optimal CD8 cell responses. We report that BALB/c mice first immunized as neonates (7 days) with a Plasmodium yoelii circumsporozoite protein (PyCSP) DNA vaccine mixed with a plasmid expressing murine GM-CSF (DG) and boosted at 28 days with poxvirus expressing PyCSP were protected (93%) as well as mice immunized entirely as adults (70%). Protection was dependent on CD8 cells, and mice had excellent anti-PyCSP IFN-gamma and cytotoxic T lymphocyte responses. Mice born of mothers previously exposed to P. yoelii parasites or immunized with the vaccine were protected and had excellent T cell responses. These data support assessment of this immunization strategy in neonates/young infants in areas in which malaria exacts its greatest toll.
在非洲的一些地区,50%归因于疟疾的死亡发生在8个月以下的婴儿中。因此,疟疾免疫可能必须在新生儿期开始,此时新生儿具有母体获得的针对疟原虫蛋白的抗体。许多正在研发的疟疾疫苗依赖CD8细胞作为免疫效应器。一些研究表明,新生儿不会产生最佳的CD8细胞反应。我们报告,新生(7日龄)BALB/c小鼠首次用与表达鼠GM-CSF的质粒混合的约氏疟原虫环子孢子蛋白(PyCSP)DNA疫苗免疫,并在28日龄时用表达PyCSP的痘病毒加强免疫,其保护率(93%)与完全作为成年鼠免疫的小鼠(70%)相同。保护依赖于CD8细胞,且小鼠具有良好的抗PyCSP IFN-γ和细胞毒性T淋巴细胞反应。先前接触过约氏疟原虫寄生虫或用该疫苗免疫的母亲所生的小鼠受到保护,且具有良好的T细胞反应。这些数据支持在疟疾造成最大危害的地区对新生儿/幼儿评估这种免疫策略。